Actively Recruiting
Phase 1 Study to Test Safety and Tolerability of NNC1679-0001 in Healthy Adults and Adults With Type 2 Diabetes
Led by Novo Nordisk A/S · Updated on 2026-06-22
58
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a new experimental medicine called NNC1679-0001 for people with type 2 diabetes and healthy volunteers. The study aims to assess the safety and how well the body tolerates this medicine. Participants will be randomly assigned to receive either the study medicine or a placebo, which contains no active drug, in a double-blinded and placebo-controlled Phase 1 trial. Participants will receive a single dose of NNC1679-0001 or placebo through an injection under the skin near the abdomen. The study includes two groups healthy participants and those with type 2 diabetes. The assignment to treatment groups is by chance, and all doses are given once. The study medicine is not yet available through regular medical prescriptions. During the study, participants will be monitored for treatment-emergent adverse events from the day of dosing up to 34 weeks. Various assessments include blood tests to measure the drug concentration over time and the number of hypoglycemic episodes. Participants will also have physical exams, vital sign checks, and other safety evaluations throughout the trial period, which lasts until June 2028.
CONDITIONS
Brief Title
A Research Study to Evaluate the Safety of NNC1679-0001 When Given to Healthy Participants and Participants With T2DM
Research Team
N
Novo Nordisk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
